IBDEI2V2 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,45640,1,4,0)
;;=4^I80.201
;;^UTILITY(U,$J,358.3,45640,2)
;;=^5007828
;;^UTILITY(U,$J,358.3,45641,0)
;;=I80.202^^172^2274^5
;;^UTILITY(U,$J,358.3,45641,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45641,1,3,0)
;;=3^Phlebitis & thrombophlebitis deep vessels, left lower extremities
;;^UTILITY(U,$J,358.3,45641,1,4,0)
;;=4^I80.202
;;^UTILITY(U,$J,358.3,45641,2)
;;=^5007829
;;^UTILITY(U,$J,358.3,45642,0)
;;=I80.203^^172^2274^6
;;^UTILITY(U,$J,358.3,45642,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45642,1,3,0)
;;=3^Phlebitis & thrombophlebitis deep vessels, bilateral lower extremities
;;^UTILITY(U,$J,358.3,45642,1,4,0)
;;=4^I80.203
;;^UTILITY(U,$J,358.3,45642,2)
;;=^5007830
;;^UTILITY(U,$J,358.3,45643,0)
;;=I80.3^^172^2274^7
;;^UTILITY(U,$J,358.3,45643,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45643,1,3,0)
;;=3^Phlebitis & thrombophlebitis of lower extremities, unspec
;;^UTILITY(U,$J,358.3,45643,1,4,0)
;;=4^I80.3
;;^UTILITY(U,$J,358.3,45643,2)
;;=^5007845
;;^UTILITY(U,$J,358.3,45644,0)
;;=I95.9^^172^2274^2
;;^UTILITY(U,$J,358.3,45644,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45644,1,3,0)
;;=3^Hypotension, unspecified
;;^UTILITY(U,$J,358.3,45644,1,4,0)
;;=4^I95.9
;;^UTILITY(U,$J,358.3,45644,2)
;;=^5008080
;;^UTILITY(U,$J,358.3,45645,0)
;;=Z51.81^^172^2275^23
;;^UTILITY(U,$J,358.3,45645,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45645,1,3,0)
;;=3^Therapeutic Drug Level Monitoring
;;^UTILITY(U,$J,358.3,45645,1,4,0)
;;=4^Z51.81
;;^UTILITY(U,$J,358.3,45645,2)
;;=^5063064
;;^UTILITY(U,$J,358.3,45646,0)
;;=D68.51^^172^2275^1
;;^UTILITY(U,$J,358.3,45646,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45646,1,3,0)
;;=3^Activated Protein C Resistance
;;^UTILITY(U,$J,358.3,45646,1,4,0)
;;=4^D68.51
;;^UTILITY(U,$J,358.3,45646,2)
;;=^5002358
;;^UTILITY(U,$J,358.3,45647,0)
;;=I82.402^^172^2275^2
;;^UTILITY(U,$J,358.3,45647,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45647,1,3,0)
;;=3^Acute Embolism/Thrombos Deep Veins Left Lower Extremity
;;^UTILITY(U,$J,358.3,45647,1,4,0)
;;=4^I82.402
;;^UTILITY(U,$J,358.3,45647,2)
;;=^5007855
;;^UTILITY(U,$J,358.3,45648,0)
;;=I82.401^^172^2275^3
;;^UTILITY(U,$J,358.3,45648,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45648,1,3,0)
;;=3^Acute Embolism/Thrombos Deep Veins Right Lower Extremity
;;^UTILITY(U,$J,358.3,45648,1,4,0)
;;=4^I82.401
;;^UTILITY(U,$J,358.3,45648,2)
;;=^5007854
;;^UTILITY(U,$J,358.3,45649,0)
;;=I82.890^^172^2275^4
;;^UTILITY(U,$J,358.3,45649,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45649,1,3,0)
;;=3^Acute Embolism/Thrombosis of Specified Veins
;;^UTILITY(U,$J,358.3,45649,1,4,0)
;;=4^I82.890
;;^UTILITY(U,$J,358.3,45649,2)
;;=^5007938
;;^UTILITY(U,$J,358.3,45650,0)
;;=D68.61^^172^2275^5
;;^UTILITY(U,$J,358.3,45650,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45650,1,3,0)
;;=3^Antiphospholipid Syndrome
;;^UTILITY(U,$J,358.3,45650,1,4,0)
;;=4^D68.61
;;^UTILITY(U,$J,358.3,45650,2)
;;=^185421
;;^UTILITY(U,$J,358.3,45651,0)
;;=I63.50^^172^2275^6
;;^UTILITY(U,$J,358.3,45651,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45651,1,3,0)
;;=3^Cerebral Infarction d/t Occls/Stenos of Cereb Artery
;;^UTILITY(U,$J,358.3,45651,1,4,0)
;;=4^I63.50
;;^UTILITY(U,$J,358.3,45651,2)
;;=^5007343
;;^UTILITY(U,$J,358.3,45652,0)
;;=I82.91^^172^2275^7
;;^UTILITY(U,$J,358.3,45652,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2V2 3777 printed Nov 22, 2024@17:46:33 Page 2
IBDEI2V2 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,45640,1,4,0)
+2 ;;=4^I80.201
+3 ;;^UTILITY(U,$J,358.3,45640,2)
+4 ;;=^5007828
+5 ;;^UTILITY(U,$J,358.3,45641,0)
+6 ;;=I80.202^^172^2274^5
+7 ;;^UTILITY(U,$J,358.3,45641,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,45641,1,3,0)
+10 ;;=3^Phlebitis & thrombophlebitis deep vessels, left lower extremities
+11 ;;^UTILITY(U,$J,358.3,45641,1,4,0)
+12 ;;=4^I80.202
+13 ;;^UTILITY(U,$J,358.3,45641,2)
+14 ;;=^5007829
+15 ;;^UTILITY(U,$J,358.3,45642,0)
+16 ;;=I80.203^^172^2274^6
+17 ;;^UTILITY(U,$J,358.3,45642,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,45642,1,3,0)
+20 ;;=3^Phlebitis & thrombophlebitis deep vessels, bilateral lower extremities
+21 ;;^UTILITY(U,$J,358.3,45642,1,4,0)
+22 ;;=4^I80.203
+23 ;;^UTILITY(U,$J,358.3,45642,2)
+24 ;;=^5007830
+25 ;;^UTILITY(U,$J,358.3,45643,0)
+26 ;;=I80.3^^172^2274^7
+27 ;;^UTILITY(U,$J,358.3,45643,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,45643,1,3,0)
+30 ;;=3^Phlebitis & thrombophlebitis of lower extremities, unspec
+31 ;;^UTILITY(U,$J,358.3,45643,1,4,0)
+32 ;;=4^I80.3
+33 ;;^UTILITY(U,$J,358.3,45643,2)
+34 ;;=^5007845
+35 ;;^UTILITY(U,$J,358.3,45644,0)
+36 ;;=I95.9^^172^2274^2
+37 ;;^UTILITY(U,$J,358.3,45644,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,45644,1,3,0)
+40 ;;=3^Hypotension, unspecified
+41 ;;^UTILITY(U,$J,358.3,45644,1,4,0)
+42 ;;=4^I95.9
+43 ;;^UTILITY(U,$J,358.3,45644,2)
+44 ;;=^5008080
+45 ;;^UTILITY(U,$J,358.3,45645,0)
+46 ;;=Z51.81^^172^2275^23
+47 ;;^UTILITY(U,$J,358.3,45645,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,45645,1,3,0)
+50 ;;=3^Therapeutic Drug Level Monitoring
+51 ;;^UTILITY(U,$J,358.3,45645,1,4,0)
+52 ;;=4^Z51.81
+53 ;;^UTILITY(U,$J,358.3,45645,2)
+54 ;;=^5063064
+55 ;;^UTILITY(U,$J,358.3,45646,0)
+56 ;;=D68.51^^172^2275^1
+57 ;;^UTILITY(U,$J,358.3,45646,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,45646,1,3,0)
+60 ;;=3^Activated Protein C Resistance
+61 ;;^UTILITY(U,$J,358.3,45646,1,4,0)
+62 ;;=4^D68.51
+63 ;;^UTILITY(U,$J,358.3,45646,2)
+64 ;;=^5002358
+65 ;;^UTILITY(U,$J,358.3,45647,0)
+66 ;;=I82.402^^172^2275^2
+67 ;;^UTILITY(U,$J,358.3,45647,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,45647,1,3,0)
+70 ;;=3^Acute Embolism/Thrombos Deep Veins Left Lower Extremity
+71 ;;^UTILITY(U,$J,358.3,45647,1,4,0)
+72 ;;=4^I82.402
+73 ;;^UTILITY(U,$J,358.3,45647,2)
+74 ;;=^5007855
+75 ;;^UTILITY(U,$J,358.3,45648,0)
+76 ;;=I82.401^^172^2275^3
+77 ;;^UTILITY(U,$J,358.3,45648,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,45648,1,3,0)
+80 ;;=3^Acute Embolism/Thrombos Deep Veins Right Lower Extremity
+81 ;;^UTILITY(U,$J,358.3,45648,1,4,0)
+82 ;;=4^I82.401
+83 ;;^UTILITY(U,$J,358.3,45648,2)
+84 ;;=^5007854
+85 ;;^UTILITY(U,$J,358.3,45649,0)
+86 ;;=I82.890^^172^2275^4
+87 ;;^UTILITY(U,$J,358.3,45649,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,45649,1,3,0)
+90 ;;=3^Acute Embolism/Thrombosis of Specified Veins
+91 ;;^UTILITY(U,$J,358.3,45649,1,4,0)
+92 ;;=4^I82.890
+93 ;;^UTILITY(U,$J,358.3,45649,2)
+94 ;;=^5007938
+95 ;;^UTILITY(U,$J,358.3,45650,0)
+96 ;;=D68.61^^172^2275^5
+97 ;;^UTILITY(U,$J,358.3,45650,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,45650,1,3,0)
+100 ;;=3^Antiphospholipid Syndrome
+101 ;;^UTILITY(U,$J,358.3,45650,1,4,0)
+102 ;;=4^D68.61
+103 ;;^UTILITY(U,$J,358.3,45650,2)
+104 ;;=^185421
+105 ;;^UTILITY(U,$J,358.3,45651,0)
+106 ;;=I63.50^^172^2275^6
+107 ;;^UTILITY(U,$J,358.3,45651,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,45651,1,3,0)
+110 ;;=3^Cerebral Infarction d/t Occls/Stenos of Cereb Artery
+111 ;;^UTILITY(U,$J,358.3,45651,1,4,0)
+112 ;;=4^I63.50
+113 ;;^UTILITY(U,$J,358.3,45651,2)
+114 ;;=^5007343
+115 ;;^UTILITY(U,$J,358.3,45652,0)
+116 ;;=I82.91^^172^2275^7
+117 ;;^UTILITY(U,$J,358.3,45652,1,0)
+118 ;;=^358.31IA^4^2
